Patient Card

Information for **Patients**

To ensure the best possible visual outcome following your treatment, it is essential that you attend all scheduled follow-up appointments.

	TREATED EYE	
	☐ Left Eye	☐ Right Eye
Date of Follow-up		
Date of Follow-up		
Date of Follow-up		

Important Information for Patients:

Importance of reporting side-effects: This medicinal product is subject to additional monitoring. If you get any side effects, talk to your doctor, pharmacist or nurse. By reporting side effects, you can help provide more information on the safety of this medicine. You can report side effects directly to HPRA Pharmacovigilance at www.hpra.ie. Side effects can also be reported to Novartis preferably at www.novartis.com/report, by emailing drugsafety.dublin@novartis.com or by calling (01) 2080 612.

The information on this card is available as a large print format and an audio file and can be found at www.voretigeneneparvovec.support/ie. If you require any additional hard copies of this piece please contact your physician.

Information for **Heathcare Professionals**

Patient name: .....

	TREATED EYE	
	☐ Left Eye	☐ Right Eye
Date of treatment		
Voretigene neparvovec batch number		

Treating ophthalmologist

Name: .....

Phone number: .....

Information for Healthcare Professionals: The holder of this card has received voretigene neparvovec, an adeno-associated virus vector based gene therapy.

Importance of reporting Adverse Events:

▼ This medicinal product is subject to additional monitoring. Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk profile of the medicinal product. All suspected adverse reactions should be reported to HPRA Pharmacovigilance at www.hpra.ie. Adverse events can also be reported to Novartis preferably at www.novartis.com/report, by emailing drugsafety.dublin@novartis.com or by calling (01) 2080 612.

The information on this card is available as a large print format and an audio file and can be found at www.voretigeneneparvovec.support/ie. If you require any additional hard copies of this piece for your patient please contact your Novartis representative.

HPRA approved – February 2021 IE382033 I December 2023

NOVARTIS